Cargando…

D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy

Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [(68)Ga]PentixaFor has intrinsic diagnostic value and is used to select patients for personalized CXCR4-targeted radionuclide therapy with its therapeutic radiopharmaceutical companion [(177)Lu]PentixaTher. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Luyten, Kaat, Van Loy, Tom, Cawthorne, Christopher, Deroose, Christophe M., Schols, Dominique, Bormans, Guy, Cleeren, Frederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537445/
https://www.ncbi.nlm.nih.gov/pubmed/34683912
http://dx.doi.org/10.3390/pharmaceutics13101619
_version_ 1784588253012164608
author Luyten, Kaat
Van Loy, Tom
Cawthorne, Christopher
Deroose, Christophe M.
Schols, Dominique
Bormans, Guy
Cleeren, Frederik
author_facet Luyten, Kaat
Van Loy, Tom
Cawthorne, Christopher
Deroose, Christophe M.
Schols, Dominique
Bormans, Guy
Cleeren, Frederik
author_sort Luyten, Kaat
collection PubMed
description Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [(68)Ga]PentixaFor has intrinsic diagnostic value and is used to select patients for personalized CXCR4-targeted radionuclide therapy with its therapeutic radiopharmaceutical companion [(177)Lu]PentixaTher. However, a CXCR4-targeting radiopharmaceutical labeled with fluorine-18 is still of high value due to its favorable characteristics over gallium-68. Furthermore, clinical results with [(177)Lu]PentixaTher are promising, but there is still room for improvement regarding pharmacokinetics and dosimetry profile. Therefore, this study aimed to develop innovative CXCR4-targeting radiopharmaceuticals, both for diagnostic and therapeutic purposes, starting from a D-amino acid-based peptide probe (DV1-k-(DV3)) that conserves high CXCR4 binding affinity after radiolabeling. AlF-NOTA-DV1-k-(DV3) showed similar in vitro binding affinity to human CXCR4 (hCXCR4) compared to [(nat)Ga]PentixaFor (half-maximal inhibitory concentration (IC(50)): 5.3 ± 0.9 nM and 8.6 ± 1.1 nM, respectively) and also binds to murine CXCR4 (mCXCR4) (IC(50): 33.4 ± 13.5 nM) while [(nat)Ga]PentixaFor is selective for hCXCR4 (IC(50) > 1000 nM for mCXCR4). Both the diagnostic radiotracers based on the DV1-k-(DV3) vector platform, [(18)F]AlF-NOTA-DV1-k-(DV3) and [(68)Ga]Ga-DOTA-DV1-k-(DV3), and their therapeutic companion [(177)Lu]Lu-DOTA-DV1-k-(DV3) were successfully produced in high yield, demonstrated high in vitro and in vivo stability, and have the same favorable pharmacokinetic profile. Furthermore, in wild-type mice and a hCXCR4-expressing tumor model, [(18)F]AlF-NOTA-DV1-k-(DV3) shows CXCR4-specific targeting in mCXCR4-expressing organs such as liver (mean standardized uptake value (SUV(mean)) 8.2 ± 1.0 at 75 min post-injection (p.i.)), spleen (SUV(mean) 2.5 ± 1.0 at 75 min p.i.), and bone (SUV(mean) 0.4 ± 0.1 at 75 min p.i., femur harboring bone marrow) that can be blocked with the CXCR4 antagonist AMD3100. However, in a hCXCR4-expressing tumor model, tumor uptake of [(18)F]AlF-NOTA-DV1-k-(DV3) was significantly lower (SUV(mean) 0.6 ± 0.2) compared to [(68)Ga]PentixaFor (SUV(mean) 2.9). This might be explained by the high affinity of [(18)F]AlF-NOTA-DV1-k-(DV3) toward both mCXCR4 and hCXCR4. High mCXCR4 expression in mouse liver results in a large fraction of [(18)F]AlF-NOTA-DV1-k-(DV3) that is sequestered to the liver, resulting despite its similar in vitro affinity for hCXCR4, in lower tumor accumulation compared to [(68)Ga]PentixaFor. As CXCR4 is not expressed in healthy human liver, the findings in mice are not predictive for the potential clinical performance of this novel class of CXCR4-targeting radiotracers. In conclusion, the DV1-k-(DV3) scaffold is a promising vector platform for translational CXCR4-directed research.
format Online
Article
Text
id pubmed-8537445
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85374452021-10-24 D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy Luyten, Kaat Van Loy, Tom Cawthorne, Christopher Deroose, Christophe M. Schols, Dominique Bormans, Guy Cleeren, Frederik Pharmaceutics Article Positron emission tomography (PET) imaging of the C-X-C chemokine receptor 4 (CXCR4) with [(68)Ga]PentixaFor has intrinsic diagnostic value and is used to select patients for personalized CXCR4-targeted radionuclide therapy with its therapeutic radiopharmaceutical companion [(177)Lu]PentixaTher. However, a CXCR4-targeting radiopharmaceutical labeled with fluorine-18 is still of high value due to its favorable characteristics over gallium-68. Furthermore, clinical results with [(177)Lu]PentixaTher are promising, but there is still room for improvement regarding pharmacokinetics and dosimetry profile. Therefore, this study aimed to develop innovative CXCR4-targeting radiopharmaceuticals, both for diagnostic and therapeutic purposes, starting from a D-amino acid-based peptide probe (DV1-k-(DV3)) that conserves high CXCR4 binding affinity after radiolabeling. AlF-NOTA-DV1-k-(DV3) showed similar in vitro binding affinity to human CXCR4 (hCXCR4) compared to [(nat)Ga]PentixaFor (half-maximal inhibitory concentration (IC(50)): 5.3 ± 0.9 nM and 8.6 ± 1.1 nM, respectively) and also binds to murine CXCR4 (mCXCR4) (IC(50): 33.4 ± 13.5 nM) while [(nat)Ga]PentixaFor is selective for hCXCR4 (IC(50) > 1000 nM for mCXCR4). Both the diagnostic radiotracers based on the DV1-k-(DV3) vector platform, [(18)F]AlF-NOTA-DV1-k-(DV3) and [(68)Ga]Ga-DOTA-DV1-k-(DV3), and their therapeutic companion [(177)Lu]Lu-DOTA-DV1-k-(DV3) were successfully produced in high yield, demonstrated high in vitro and in vivo stability, and have the same favorable pharmacokinetic profile. Furthermore, in wild-type mice and a hCXCR4-expressing tumor model, [(18)F]AlF-NOTA-DV1-k-(DV3) shows CXCR4-specific targeting in mCXCR4-expressing organs such as liver (mean standardized uptake value (SUV(mean)) 8.2 ± 1.0 at 75 min post-injection (p.i.)), spleen (SUV(mean) 2.5 ± 1.0 at 75 min p.i.), and bone (SUV(mean) 0.4 ± 0.1 at 75 min p.i., femur harboring bone marrow) that can be blocked with the CXCR4 antagonist AMD3100. However, in a hCXCR4-expressing tumor model, tumor uptake of [(18)F]AlF-NOTA-DV1-k-(DV3) was significantly lower (SUV(mean) 0.6 ± 0.2) compared to [(68)Ga]PentixaFor (SUV(mean) 2.9). This might be explained by the high affinity of [(18)F]AlF-NOTA-DV1-k-(DV3) toward both mCXCR4 and hCXCR4. High mCXCR4 expression in mouse liver results in a large fraction of [(18)F]AlF-NOTA-DV1-k-(DV3) that is sequestered to the liver, resulting despite its similar in vitro affinity for hCXCR4, in lower tumor accumulation compared to [(68)Ga]PentixaFor. As CXCR4 is not expressed in healthy human liver, the findings in mice are not predictive for the potential clinical performance of this novel class of CXCR4-targeting radiotracers. In conclusion, the DV1-k-(DV3) scaffold is a promising vector platform for translational CXCR4-directed research. MDPI 2021-10-05 /pmc/articles/PMC8537445/ /pubmed/34683912 http://dx.doi.org/10.3390/pharmaceutics13101619 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Luyten, Kaat
Van Loy, Tom
Cawthorne, Christopher
Deroose, Christophe M.
Schols, Dominique
Bormans, Guy
Cleeren, Frederik
D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title_full D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title_fullStr D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title_full_unstemmed D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title_short D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
title_sort d-peptide-based probe for cxcr4-targeted molecular imaging and radionuclide therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537445/
https://www.ncbi.nlm.nih.gov/pubmed/34683912
http://dx.doi.org/10.3390/pharmaceutics13101619
work_keys_str_mv AT luytenkaat dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT vanloytom dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT cawthornechristopher dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT deroosechristophem dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT scholsdominique dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT bormansguy dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy
AT cleerenfrederik dpeptidebasedprobeforcxcr4targetedmolecularimagingandradionuclidetherapy